Hey, this is Stocks_Pedia.
I would like to introduce some unfamiliar companies that may be of some help to your investments.
The company I’m going to introduce is $89Bio, Inc.(ETNB)$.
It went public on 11th November 2019.
[Company Profile]
89Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.
The Company's lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
NASH is a severe form of nonalcoholic fatty liver disease (NAFLD), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, hepatocellular carcinoma (HCC) and death.
The Company is evaluating the potential opportunity for pegozafermin in these fibrosis stage F4 patients. SHTG is a condition identified by severely elevated levels of triglycerides. The Company has initiated its Phase II trial (ENTRIGUE) in SHTG patients.
[History & Events]
2018: 89bio, Inc. was incorporated and is headquartered in San Francisco, California. The company announced it has closed a $60 million Series A financing on Oct 25, 2018.
2019: The company went public and the stock price surged.
2020: Teva spin-off 89bio raised $84m in Nasdaq secondary offering.
2021: 89bio participated in the Cantor Global Healthcare Conference and in November presented new data from Phase 1b/2a NASH Study showing BIO89-100 reduces Spleen Volume.
2022: 89bio announced appointment of E. Morrey Atkinson, Ph.D., to its board of directors.
[Net Income & Total Revenue]
[Competitors]
-Alembic Pharmaceuticals
-EMS Pharma
-Genentech
Comments